CA2909994C - Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level - Google Patents

Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level Download PDF

Info

Publication number
CA2909994C
CA2909994C CA2909994A CA2909994A CA2909994C CA 2909994 C CA2909994 C CA 2909994C CA 2909994 A CA2909994 A CA 2909994A CA 2909994 A CA2909994 A CA 2909994A CA 2909994 C CA2909994 C CA 2909994C
Authority
CA
Canada
Prior art keywords
general formula
tamoxifen
derivative
triphenylphosphonium
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909994A
Other languages
English (en)
French (fr)
Other versions
CA2909994A1 (en
Inventor
Jiri Neuzil
Lukas Werner
Jan Stursa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOTECHNOLOGICKY USTAV AV CR VVI
Smart Brain sro
Springtide Ventures SRO
Original Assignee
Kkcg AG
BIOTECHNOLOGICKY USTAV AV CR VVI
Smart Brain sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2909994(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Kkcg AG, BIOTECHNOLOGICKY USTAV AV CR VVI, Smart Brain sro filed Critical Kkcg AG
Publication of CA2909994A1 publication Critical patent/CA2909994A1/en
Application granted granted Critical
Publication of CA2909994C publication Critical patent/CA2909994C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
CA2909994A 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level Active CA2909994C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZPV2013-308 2013-04-24
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZPV2014-66 2014-01-29
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (2)

Publication Number Publication Date
CA2909994A1 CA2909994A1 (en) 2014-10-30
CA2909994C true CA2909994C (en) 2018-06-26

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909994A Active CA2909994C (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Country Status (21)

Country Link
US (1) US9896466B2 (enExample)
EP (1) EP2989110B1 (enExample)
JP (1) JP6375091B2 (enExample)
KR (1) KR101764991B1 (enExample)
CN (1) CN105452265B (enExample)
AU (1) AU2014256546B2 (enExample)
CA (1) CA2909994C (enExample)
CY (1) CY1120821T1 (enExample)
DK (1) DK2989110T3 (enExample)
EA (1) EA029881B1 (enExample)
ES (1) ES2699099T3 (enExample)
GE (1) GEP20186868B (enExample)
HR (1) HRP20181872T1 (enExample)
HU (1) HUE042239T2 (enExample)
MD (1) MD4626C1 (enExample)
NZ (1) NZ713589A (enExample)
PL (1) PL2989110T3 (enExample)
PT (1) PT2989110T (enExample)
SI (1) SI2989110T1 (enExample)
UA (1) UA116469C2 (enExample)
WO (1) WO2014173374A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548318B2 (en) * 2015-07-03 2020-02-04 Bayer Cropscience Aktiengesellschaft N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action
WO2017005564A1 (de) * 2015-07-03 2017-01-12 Bayer Cropscience Aktiengesellschaft Herbizid wirksame n-(1,3,4-oxadiazol-2-yl)arylcarboxamid-derivate
WO2018013559A1 (en) * 2016-07-12 2018-01-18 Accutar Biotechnology Inc. Novel compounds and uses thereof
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
BR112020008022A2 (pt) 2017-10-24 2020-10-27 Lunella Biotech, Inc. mitoflavoscinas: o direcionamento de enzimas contendo flavina elimina as células-tronco de câncer (cscs) por meio da inibição da respiração mitocondrial
US10980821B2 (en) 2017-11-24 2021-04-20 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
WO2019126179A1 (en) 2017-12-20 2019-06-27 Lunella Biotech, Inc. Targeting mitochondrial fission through mdivi-1 derivatives
US20220211728A1 (en) * 2019-04-16 2022-07-07 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551434B1 (en) * 1990-10-01 1995-11-15 The Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
IL173807A (en) * 2003-08-22 2014-02-27 Antipodean Pharmaceuticals Inc Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them
JP2008506667A (ja) * 2004-07-13 2008-03-06 オリディス・ビオメド・フォルシュングス−ウント・エントヴィックルングス・ゲーエムベーハー 肝疾患及び上皮性癌の治療におけるミトコンドリアを標的とした酸化防止剤
JP5616798B2 (ja) * 2008-03-14 2014-10-29 スティーブン・ジョン・ラルフＳｔｅｐｈｅｎ Ｊｏｈｎ ＲＡＬＰＨ ミトコンドリア由来の抗ガン化合物
CA2756820A1 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
EP2989110B1 (en) 2018-08-08
EA201591918A1 (ru) 2016-02-29
WO2014173374A1 (en) 2014-10-30
MD4626C1 (ro) 2019-11-30
PL2989110T3 (pl) 2019-03-29
HK1216317A1 (zh) 2016-11-04
HRP20181872T1 (hr) 2019-02-08
EP2989110A1 (en) 2016-03-02
CA2909994A1 (en) 2014-10-30
NZ713589A (en) 2017-12-22
JP2016522179A (ja) 2016-07-28
MD20150117A2 (ro) 2016-08-31
JP6375091B2 (ja) 2018-08-15
KR101764991B1 (ko) 2017-08-10
HUE042239T2 (hu) 2019-06-28
MD4626B1 (ro) 2019-04-30
ES2699099T3 (es) 2019-02-07
AU2014256546B2 (en) 2017-03-30
UA116469C2 (uk) 2018-03-26
CN105452265A (zh) 2016-03-30
EA029881B1 (ru) 2018-05-31
CY1120821T1 (el) 2019-12-11
PT2989110T (pt) 2018-11-15
US20160075726A1 (en) 2016-03-17
US9896466B2 (en) 2018-02-20
GEP20186868B (en) 2018-06-25
KR20150144756A (ko) 2015-12-28
SI2989110T1 (sl) 2019-01-31
CN105452265B (zh) 2017-05-10
AU2014256546A1 (en) 2015-11-12
DK2989110T3 (en) 2018-12-03

Similar Documents

Publication Publication Date Title
CA2909994C (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
Burmaoglu et al. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents
Xu et al. Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents
Jaouen et al. Ferrocifen type anti cancer drugs
JP2016522179A5 (enExample)
Sun et al. Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR
El Abbouchi et al. Synthesis and evaluation of a novel class of ethacrynic acid derivatives containing triazoles as potent anticancer agents
Mohassab et al. Design and synthesis of new quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases
Yang et al. A novel drug prejudice scaffold-imidazopyridine-conjugate can promote cell death in a colorectal cancer model by binding to β-catenin and suppressing the Wnt signaling pathway
Shan et al. First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
Vosooghi et al. Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs
AU2016212552B2 (en) Compound containing indoleacetic acid core structure and use thereof
Luo et al. Discovery of 3-(2-aminobenzo [d] thiazol-5-yl) benzamide derivatives as potent anticancer agents via ROR1 inhibition
CZ2013308A3 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
Chacko et al. Novel thiosemicarbazide hybrids with amino acids and peptides against hepatocellular carcinoma: a molecular designing approach towards multikinase inhibitor
JP6423349B2 (ja) Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用
Usman et al. A novel biocompatible formate bridged 1D-Cu (ii) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells
CZ201466A3 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
Liu et al. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-N-arylacetamides as novel HSP90 C-terminal inhibitors
Alotaibi Design, synthesis and biological evaluation of novel estradiol-triazole analogs targeting epidermal growth factor receptors in colorectal cancer
Becerril et al. Evaluation of the effect of 1, 3-Bis (4-Phenyl)-1H-1, 2, 3-Triazolyl-2-propanolol on gene expression levels of JAK2–STAT3, NF-κB, and SOCS3 in cells cultured from biopsies of mammary lesions
Khalaf Alshamari et al. Exploration of Novel 2, 6-Bis (1-Aryl-1, 2, 3-Triazol-4-yl) Pyridine Derivatives: Synthesis, Apoptotic Antiproliferative Evaluation, and In silico Insight as EGFR Inhibitors
WO2025129032A1 (en) Chd1l inhibitors for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151021

EEER Examination request

Effective date: 20151021